Two Federal Transparency Bills Introduced In Congress

CL
Cooley LLP

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Two new federal bills have been introduced in Congress related to manufacturer transparency.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Two new federal bills have been introduced in Congress related to manufacturer transparency. Senate Bill 2891 (S. 2891), the Fighting the Opioid Epidemic with Sunshine Act of 2018, was recently introduced by Senators Grassley, Brown and Blumenthal. S. 2891 would amend the current Open Payments law to require annual reporting of payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives.

Similarly, the recently introduced Patient Advocacy Transparency Act also would amend the Open Payments law to:

  • Define "grant" to include education grants and capacity building grants;
  • Add to the list of payments or transfers of value that must be reported annually: (i) fundraising event sponsorship; (ii) meeting or conference expenses not already reportable; and (iii) funding of marketing, public relations activities, placement on television programs or internet websites, or social media support; and
  • Expand the definition of "covered entity" to include (i) professional society of health care providers or pharmacists; (ii) patient advocacy organization, consumer advocacy organization, voluntary health agency, or a coalition of such organizations, including a disease-specific advocacy organization; (iii) patient education organization; (iv) continuing education providers, including a medical education or
    communications company; (v) clinical trial organization; (vi) education accreditation organization; (vii) co-pay assistance organization or other organization providing financial assistance to patients; and (viii) foundation established by one of these entities.

These bills include bipartisan support for a trending area within federal and state legislatures to increase transparency related to manufacturer activities, including payments and transfers of value to third parties and product pricing. We will continue to monitor these laws and update the blog accordingly.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More